Phase 1 Open-label, Dose-escalation Clinical Study of the Safety and Tolerability of RGB-286638, a Novel, Multi-targeted Kinase Inhibitor, Administered to Patients With Selected, Relapsed or Refractory Hematological Malignancies.

Trial Profile

Phase 1 Open-label, Dose-escalation Clinical Study of the Safety and Tolerability of RGB-286638, a Novel, Multi-targeted Kinase Inhibitor, Administered to Patients With Selected, Relapsed or Refractory Hematological Malignancies.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2012

At a glance

  • Drugs RGB 286638 (Primary)
  • Indications Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Mantle-cell lymphoma; Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Aug 2011 Actual initiation date (1 Nov 2011) added as reported by ClinicalTrials.gov.
    • 04 Aug 2011 Status changed from not yet recruiting to withdrawn prior to recruitment (withdrawn prior to recruitment).
    • 07 Jun 2011 Planned initiation date changed from 1 Nov 2010 to 1 Nov 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top